Literature DB >> 15806322

Incidence and causes for failure of treatment of women with proven osteoporosis.

Noah Zafran1, Zvi Liss, Ronit Peled, Michael Sherf, Haim Reuveni.   

Abstract

The purpose of this study was to examine factors influencing women's compliance with medical therapy for osteoporosis in Israel. The study population consisted of women diagnosed with osteoporosis using a DEXA examination in the year 2000. Medication purchases for a period of 13 months after the exam were analyzed. Data were gathered from the computerized data base of Clalit Health Care Services and phone interviews. Treatment was divided into specific drugs and food additives (preparation of calcium plus vitamin D). Full, intermediate, low and no compliance were defined as >80, 50-80, 25-50 and <25% of treatment days, respectively. In the study, 857 women with a mean age of 73.6 years were enrolled; 581 (67.8%) were interviewed by telephone. Most of women were undereducated and unemployed. Twenty percent did not purchase any specific drug; 4.5% did not purchase any drug or food additive for osteoporosis; 60% were fully or intermittently compliant (by purchasing) with drug therapy. The most frequent single specific drugs purchased were bisphosphanates and SERM: 62.3 and 76.3% purchased bisphosphanates and/or food additives, respectively. Multi-variant analysis showed that predictors of compliance were healthy women, compliant with calcium plus vitamin D preparations, and/or spending more on drugs. Reasons for low or non-compliance were inconsistent recommendations by various physicians and the side effects of specific drugs. The relatively high compliance rate of osteoporosis treatment may be attributed to the increase in awareness of its benefits. The effect of physicians on compliance needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15806322     DOI: 10.1007/s00198-005-1838-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  39 in total

1.  The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization.

Authors:  B L Harris; A Stergachis; L D Ried
Journal:  Med Care       Date:  1990-10       Impact factor: 2.983

2.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors:  C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

3.  Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures.

Authors:  H Castel; D Y Bonneh; M Sherf; Y Liel
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

4.  Prevalence of osteoporosis and related risk factors in UK women in the seventh decade: osteoporosis case finding by clinical referral criteria or predictive model?

Authors:  P A Ballard; D W Purdie; C M Langton; S A Steel; S Mussurakis
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

5.  Determinants of long-term hormone replacement therapy and reasons for early discontinuation.

Authors:  I den Tonkelaar; B J Oddens
Journal:  Obstet Gynecol       Date:  2000-04       Impact factor: 7.661

6.  Compliance with pharmacologic therapy for osteoporosis.

Authors:  Robert A Yood; Srinivas Emani; John I Reed; Barbara Edelman Lewis; Mary Charpentier; Eva Lydick
Journal:  Osteoporos Int       Date:  2003-09-19       Impact factor: 4.507

7.  Osteoporosis and proximal femoral fractures in the female elderly of Jerusalem.

Authors:  M Makin
Journal:  Clin Orthop Relat Res       Date:  1987-05       Impact factor: 4.176

Review 8.  Medication compliance in the elderly.

Authors:  C Salzman
Journal:  J Clin Psychiatry       Date:  1995       Impact factor: 4.384

9.  Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study.

Authors:  James A Simon; E Michael Lewiecki; Mary E Smith; Richard A Petruschke; Lixia Wang; Joanne J Palmisano
Journal:  Clin Ther       Date:  2002-11       Impact factor: 3.393

10.  Bone mineral density in diagnosis of osteoporosis: reference population, definition of peak bone mass, and measured site determine prevalence.

Authors:  O Löfman; L Larsson; G Toss
Journal:  J Clin Densitom       Date:  2000       Impact factor: 2.963

View more
  7 in total

1.  Frequency of and reasons for medication non-fulfillment and non-persistence among American adults with chronic disease in 2008.

Authors:  Colleen A McHorney; Charles V Spain
Journal:  Health Expect       Date:  2010-09-23       Impact factor: 3.377

Review 2.  Adherence with medications used to treat osteoporosis: behavioral insights.

Authors:  John T Schousboe
Journal:  Curr Osteoporos Rep       Date:  2013-03       Impact factor: 5.096

3.  Adherence to Calcium and Vitamin D supplementations: results from the ADVICE Survey.

Authors:  Francesco Conti; Prisco Piscitelli; Giovanni Italiano; Alessandro Parma; Maria Cristina Caffetti; Lorenzo Giolli; Gian Luca Di Tanna; Andrea Guazzini; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

Review 4.  Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy.

Authors:  P Lee; H van der Wall; M J Seibel
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

Review 5.  Non-compliance: the Achilles' heel of anti-fracture efficacy.

Authors:  E Seeman; J Compston; J Adachi; M L Brandi; C Cooper; B Dawson-Hughes; B Jönsson; H Pols; J A Cramer
Journal:  Osteoporos Int       Date:  2007-01-24       Impact factor: 5.071

6.  Osteoporosis medication profile preference: results from the PREFER-US study.

Authors:  Thomas W Weiss; Colleen A McHorney
Journal:  Health Expect       Date:  2007-09       Impact factor: 3.377

7.  Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial.

Authors:  Debby den Uyl; Piet P M M Geusens; Frank N R van Berkum; Harry H M L Houben; Max C Jebbink; Willem F Lems
Journal:  Clin Rheumatol       Date:  2009-12-22       Impact factor: 2.980

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.